Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatm… Read more
Market Cap & Net Worth: Aldeyra The (ALDX)
Aldeyra The (NASDAQ:ALDX) has a market capitalization of $74.60 Million ($74.60 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20473 globally and #7432 in its home market, demonstrating a -76.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aldeyra The's stock price $1.24 by its total outstanding shares 60162773 (60.16 Million).
Aldeyra The Market Cap History: 2015 to 2026
Aldeyra The's market capitalization history from 2015 to 2026. Data shows change from $407.90 Million to $74.60 Million (-14.49% CAGR).
Index Memberships
Aldeyra The is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #565 of 976 |
Weight: Aldeyra The's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aldeyra The Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aldeyra The's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ALDX by Market Capitalization
Companies near Aldeyra The in the global market cap rankings as of March 18, 2026.
Key companies related to Aldeyra The by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aldeyra The Historical Marketcap From 2015 to 2026
Between 2015 and today, Aldeyra The's market cap moved from $407.90 Million to $ 74.60 Million, with a yearly change of -14.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $74.60 Million | -76.06% |
| 2025 | $311.64 Million | +3.81% |
| 2024 | $300.21 Million | +42.17% |
| 2023 | $211.17 Million | -49.57% |
| 2022 | $418.73 Million | +74.00% |
| 2021 | $240.65 Million | -41.69% |
| 2020 | $412.72 Million | +18.07% |
| 2019 | $349.55 Million | -30.00% |
| 2018 | $499.35 Million | +22.06% |
| 2017 | $409.11 Million | +27.10% |
| 2016 | $321.87 Million | -21.09% |
| 2015 | $407.90 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Aldeyra The was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $74.60 Million USD |
| MoneyControl | $74.60 Million USD |
| MarketWatch | $74.60 Million USD |
| marketcap.company | $74.60 Million USD |
| Reuters | $74.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.